Loading
A phase 2 trial of sintilimab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Shandong Cancer Hospital and Institute, not yet recruiting.
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT07683221 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 47 participants, started 2026-07-15 and due to reach its primary completion in 2029-07-15. Interventions recorded: SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival (PFS). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Sintilimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Sintilimab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.